After more than a decade of continuous observation, the VARGADO study has reached data hard lock.

This milestone reflects what long horizon real world research enables when data integrity regulatory rigor and operational continuity are sustained over time.

Through Alcedis - a HUMA company , a Huma company, and in collaboration with Boehringer Ingelheim, this study evaluated second and later line therapy in patients with advanced or metastatic lung adenocarcinoma.

Over 10 years, the study delivered:
• Three peer reviewed publications
• Presentation at ESMO - European Society for Medical Oncology 2024 in Berlin
• Longitudinal insight into treatment sequencing outcomes and real world clinical practice

Across 137 treated patients, the investigational therapy demonstrated high response rates and meaningful disease stabilization in the third line setting, with a manageable safety profile following chemotherapy and ICI failure.

At Huma, we build regulated data and research infrastructure designed to operate at clinical scale and over clinical timeframes supporting studies that run for years not months without compromising data quality or continuity.

Because in oncology durable insight does not come from snapshots.
It comes from systems that endure.